CD36 gene is associated with intraocular pressure elevation
after intravitreal application of anti-VEGF agents in patients
with age-related macular degeneration: Implications for the
safety of the therapy

J 2018

CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy

MATUŠKOVÁ, Veronika, Vladimír Josef BALCAR, Naim A. KHAN, Ondřej BONCZEK, Laura EWERLINGOVÁ et. al.

Basic information

Original name

CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy

Authors

MATUŠKOVÁ, Veronika (203 Czech Republic, belonging to the institution), Vladimír Josef BALCAR (36 Australia, belonging to the institution), Naim A. KHAN (250 France), Ondřej BONCZEK (203 Czech Republic, belonging to the institution), Laura EWERLINGOVÁ (703 Slovakia, belonging to the institution), Tomáš ZEMAN (203 Czech Republic, belonging to the institution), Petr KOLÁŘ (203 Czech Republic, belonging to the institution), Daniela VYSLOUŽILOVÁ (203 Czech Republic, belonging to the institution), Eva VLKOVÁ (203 Czech Republic, belonging to the institution) and Omar ŠERÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Ophthalmic Genetics, Philadelphia, Taylor & Francis, 2018, 1381-6810

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30101 Human genetics

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.285

RIV identification code

RIV/00216224:14310/18:00106909

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1080/13816810.2017.1326508

UT WoS

000428520500002

Keywords in English

Glaucoma; polymorphism; receptor; Schlemm´s canal; thrombospondin

Abstract

V originále

Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms. Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients’ DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene. Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG). Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.

Links

NV16-31207A, research and development project

Name: Genetika a epidemiologie Alzheimerovy choroby

Citovat

MATUŠKOVÁ, Veronika, Vladimír Josef BALCAR, Naim A. KHAN, Ondřej BONCZEK, Laura EWERLINGOVÁ, Tomáš ZEMAN, Petr KOLÁŘ, Daniela VYSLOUŽILOVÁ, Eva VLKOVÁ and Omar ŠERÝ. CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy. Ophthalmic Genetics. Philadelphia: Taylor & Francis, 2018, vol. 39, No 1, p. 4-10. ISSN 1381-6810. Available from: https://dx.doi.org/10.1080/13816810.2017.1326508.

@article{1386057,
   author = {Matušková, Veronika and Balcar, Vladimír Josef and Khan, Naim A. and Bonczek, Ondřej and Ewerlingová, Laura and Zeman, Tomáš and Kolář, Petr and Vysloužilová, Daniela and Vlková, Eva and Šerý, Omar},
   article_location = {Philadelphia},
   article_number = {1},
   doi = {http://dx.doi.org/10.1080/13816810.2017.1326508},
   keywords = {Glaucoma; polymorphism; receptor; Schlemm´s canal; thrombospondin},
   language = {eng},
   issn = {1381-6810},
   journal = {Ophthalmic Genetics},
   title = {CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy},
   url = {http://dx.doi.org/10.1080/13816810.2017.1326508},
   volume = {39},
   year = {2018}
}

TY  - JOUR
ID  - 1386057
AU  - Matušková, Veronika - Balcar, Vladimír Josef - Khan, Naim A. - Bonczek, Ondřej - Ewerlingová, Laura - Zeman, Tomáš - Kolář, Petr - Vysloužilová, Daniela - Vlková, Eva - Šerý, Omar
PY  - 2018
TI  - CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy
JF  - Ophthalmic Genetics
VL  - 39
IS  - 1
SP  - 4-10
EP  - 4-10
PB  - Taylor & Francis
SN  - 13816810
KW  - Glaucoma
KW  - polymorphism
KW  - receptor
KW  - Schlemm´s canal
KW  - thrombospondin
UR  - http://dx.doi.org/10.1080/13816810.2017.1326508
N2  - Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms. Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients’ DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene. Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG). Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.
ER  -

MATUŠKOVÁ, Veronika, Vladimír Josef BALCAR, Naim A. KHAN, Ondřej BONCZEK, Laura EWERLINGOVÁ, Tomáš ZEMAN, Petr KOLÁŘ, Daniela VYSLOUŽILOVÁ, Eva VLKOVÁ and Omar ŠERÝ. CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy. \textit{Ophthalmic Genetics}. Philadelphia: Taylor \&{} Francis, 2018, vol.~39, No~1, p.~4-10. ISSN~1381-6810. Available from: https://dx.doi.org/10.1080/13816810.2017.1326508.

Detailed Information on Publication Record